Predictors of multiglandular disease in primary hyperparathyroidism

Mark Thier, Sébastien Daudi, Anders Bergenfelz, Martin Almquist, Mark Thier, Sébastien Daudi, Anders Bergenfelz, Martin Almquist

Abstract

Background: Primary hyperparathyroidism (pHPT) is caused by single- or multiglandular disease (MGD). Patients with MGD have an increased risk of complications at surgery and for persistence and recurrence after surgery. The study evaluated whether preoperative clinical and biochemical characteristics could predict MGD in patients with pHPT.

Methods: We retrospectively evaluated patients operated 1989-2013 for first-time, non-hereditary pHPT. MGD was defined in patients with more than one pathological gland excised at surgery or with persistent hypercalcemia after the excision of a single pathological parathyroid gland, confirmed by histopathology. Clinical and biochemical variables were compared in patients with single- and multiglandular disease. Logistic regression was used to identify variables predicting MGD, yielding odds ratios (OR) with 95% confidence intervals (CI).

Results: There were 707 patients, of which 79 (11%) had MGD. Patients with MGD were more likely to have negative sestamibi scintigraphy than patients with single-gland disease, 15 of 49 (31%) vs. 70 of 402 (17%; p = 0.03), to suffer from diabetes (12 of 74, 16%) vs. 45 out of 626 patients (7.2%; p < 0.01) and had lower preoperative levels of urinary calcium (3.80 vs. 4.44 mmol/L; p = 0.04). Multivariable analysis identified negative scintigraphy (OR 2.42; 95% CI 1.18 to 4.79), diabetes (OR 2.75; 95% CI 1.31 to 4.97) and elevated levels of osteocalcin (OR 3.79, 95% CI: 1.75 to 8.21) as predictors of MGD.

Conclusion: Negative sestamibi scintigraphy, diabetes and elevated osteocalcin levels were predictors of MGD.

Keywords: Multiglandular disease; Negative scintigraphy; Parathyroid hyperplasia; Prediction; Primary hyperparathyroidism.

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

References

    1. Barczynski M, et al. Sporadic multiple parathyroid gland disease—a consensus report of the European Society of Endocrine Surgeons (ESES) Langenbeck’s Arch Surg. 2015;400:887–905. doi: 10.1007/s00423-015-1348-1.
    1. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236(5):543–551. doi: 10.1097/00000658-200211000-00001.
    1. Bagul A, Patel HP, Chadwick D, Harrison BJ, Balasubramanian SP. Primary hyperparathyroidism: an analysis of failure of parathyroidectomy. World J Surg. 2014;38(3):534–541. doi: 10.1007/s00268-013-2434-6.
    1. Nasiri S, Soroush A, Hashemi AP, Hedayat A, Donboli K, Mehrkhani F. Parathyroid adenoma localization. Med J Islam Repub Iran. 2012;26(3):103–109.
    1. Tezelman S, Shen W, Shaver JK, Siperstein AE, Duh QY, Klein H, Clark OH. Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy. Ann Surg. 1993;218(3):300–307. doi: 10.1097/00000658-199309000-00009.
    1. Kebebew E, Hwang J, Reiff E, Duh QY, Clark OH. Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model. Arch Surg. 2006;141(8):777–782. doi: 10.1001/archsurg.141.8.777.
    1. Mazeh H, Chen H, Leverson G, Sippel RS. Creation of a “Wisconsin index” nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg. 2013;257(1):138–141. doi: 10.1097/SLA.0b013e31825ffbe1.
    1. Sepahdari AR, Bahl M, Harari A, Kim HJ, Yeh MW, Hoang JK. Predictors of multigland disease in primary hyperparathyroidism: a scoring system with 4D-CT imaging and biochemical markers. AJNR Am J Neuroradiol. 2015;36(5):987–992. doi: 10.3174/ajnr.A4213.
    1. Repplinger D, Schaefer S, Chen H, Sippel RS. Neurocognitive dysfunction: a predictor of parathyroid hyperplasia. Surgery. 2009;146(6):1138–1143. doi: 10.1016/j.surg.2009.09.009.
    1. Schneider DF, Burke JF, Ojomo KA, Clark N, Mazeh H, Sippel RS, Chen H. Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism. Ann Surg Oncol. 2013;20(13):4205–4211. doi: 10.1245/s10434-013-3190-4.
    1. Kavanagh DO, Fitzpatrick P, Myers E, Kennelly R, Skehan SJ, Gibney RG, Hill ADK, Evoy D, McDermott EW. A predictive model of suitability for minimally invasive parathyroid surgery in the treatment of primary hyperparathyroidism [corrected] World J Surg. 2012;36(5):1175–1181. doi: 10.1007/s00268-011-1377-z.
    1. Elfenbein DM, Weber S, Schneider DF, Sippel RS, Chen H. CaPTHUS scoring model in primary hyperparathyroidism: can it eliminate the need for ioPTH testing? Ann Surg Oncol. 2015;22(4):1191–1195. doi: 10.1245/s10434-014-4080-0.
    1. Katz MH. Multivariable analysis: a practical guide for clinicians and public health researchers. 3. New York: Cambridge University Press; 2011. p. 233.
    1. Chiu KC, Chuang LM, Lee NP, Ryu JM, McGullam JL, Tsai GP, Saad MF. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism. 2000;49(11):1501–1505. doi: 10.1053/meta.2000.17708.
    1. McCarty MF. Vitamin D, parathyroid hormone, and insulin sensitivity. Am J Clin Nutr. 2004;80(5):1451–1452. doi: 10.1093/ajcn/80.5.1451.
    1. Vaidya A, Curhan GC, Paik JM, Wang M, Taylor EN. Physical activity and the risk of primary hyperparathyroidism. J Clin Endocrinol Metab. 2016;101(4):1590–1597. doi: 10.1210/jc.2015-3836.
    1. Larsson S, Jones HA, Göransson O, Degerman E, Holm C. Parathyroid hormone induces adipocyte lipolysis via PKA-mediated phosphorylation of hormone-sensitive lipase. Cell Signal. 2015;28(3):204–213. doi: 10.1016/j.cellsig.2015.12.012.
    1. Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. Eur J Epidemiol. 2015;30(8):599–614. doi: 10.1007/s10654-015-0058-x.
    1. Sabek OM, Nishimoto SK, Fraga D, Tejpal N, Ricordi C, Gaber AO. Osteocalcin effect on human beta-cells mass and function. Endocrinology. 2015;156(9):3137–3146. doi: 10.1210/EN.2015-1143.
    1. Lazaris AC, Tseleni-Balafouta S, Papathomas T, Brousalis T, Thomopoulou G, Agrogiannis G, Patsouris ES. Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur J Endocrinol. 2006;154(6):827–833. doi: 10.1530/eje.1.02168.
    1. Sayar H, Sahin M, Dogan PO, Karabulut S, Seringec N, Oguz A. Immunohistochemical expression of insulin-like growth factor-1, transforming growth factor-beta1, and vascular endothelial growth factor in parathyroid adenoma and hyperplasia. Indian J Pathol Microbiol. 2014;57(4):549–552. doi: 10.4103/0377-4929.142658.
    1. Nilsson IL, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery. 2016;159(1):211–217. doi: 10.1016/j.surg.2015.06.057.
    1. Arvai K, et al. Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res. 2012;18(3):607–614. doi: 10.1007/s12253-011-9483-7.
    1. Backdahl M, Howe JR, Lairmore TC, Wells Jr SA. The molecular biology of parathyroid disease. World J Surg. 1991;15(6):756–762. doi: 10.1007/BF01665311.
    1. Bergenfelz AO, et al. Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound. Langenbeck's Arch Surg. 2011;396(1):83–90. doi: 10.1007/s00423-010-0724-0.
    1. Calo PG, et al. Surgery for primary hyperparathyroidism in patients with preoperatively negative sestamibi scan and discordant imaging studies: the usefulness of intraoperative parathyroid hormone monitoring. Clin Med Insights Endocrinol Diabetes. 2013;6:63–67. doi: 10.4137/CMED.S13114.
    1. Elaraj DM, Sippel RS, Lindsay S, Sansano I, Duh QY, Clark OH, Kebebew E. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg. 2010;145(6):578–581. doi: 10.1001/archsurg.2010.108.
    1. Kandil E, Malazai AJ, Alrasheedi S, Tufano RP. Minimally invasive/focused parathyroidectomy in patients with negative sestamibi scan results. Arch Otolaryngol Head Neck Surg. 2012;138(3):223–225. doi: 10.1001/archoto.2011.1419.
    1. Mihai R, Gleeson F, Buley ID, Roskell DE, Sadler GP. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. World J Surg. 2006;30(5):697–704. doi: 10.1007/s00268-005-0338-9.
    1. Sebag F, Hubbard JGH, Maweja S, Misso C, Tardivet L, Henry JF. Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism. Surgery. 2003;134(6):1038–1041. doi: 10.1016/j.surg.2003.07.021.
    1. Slitt GT, Lavery H, Morgan A, Bernstein B, Slavin J, Karimeddini MK, Kozol RA. Hyperparathyroidism but a negative sestamibi scan: a clinical dilemma. Am J Surg. 2005;190(5):708–712. doi: 10.1016/j.amjsurg.2005.07.007.
    1. Wachtel H, Bartlett EK, Kelz RR, Cerullo I, Karakousis GC, Fraker DL. Primary hyperparathyroidism with negative imaging: a significant clinical problem. Ann Surg. 2014;260(3):474–480. doi: 10.1097/SLA.0000000000000875.
    1. Thakur A, Sebag F, Slotema E, Ippolito G, Taïeb D, Henry JF. Significance of biochemical parameters in differentiating uniglandular from multiglandular disease and limiting use of intraoperative parathormone assay. World J Surg. 2009;33(6):1219–1223. doi: 10.1007/s00268-009-0029-z.
    1. Almquist M, Bergenfelz A, Mårtensson H, Thier M, Nordenström E. Changing biochemical presentation of primary hyperparathyroidism. Langenbeck’s Arch Surg. 2010;395(7):925–928. doi: 10.1007/s00423-010-0675-5.
    1. Lo CY, Chan WF, Kung AW, Lam KY, Tam SC, Lam KS. Surgical treatment for primary hyperparathyroidism in Hong Kong: changes in clinical pattern over 3 decades. Arch Surg. 2004;139(1):77–82. doi: 10.1001/archsurg.139.1.77.
    1. Mazzaglia PJ, Berber E, Kovach A, Milas M, Esselstyn C, Siperstein AE. The changing presentation of hyperparathyroidism over 3 decades. Arch Surg. 2008;143(3):260–266. doi: 10.1001/archsurg.143.3.260.
    1. McCoy KL, Chen NH, Armstrong MJ, Howell GM, Stang MT, Yip L, Carty SE. The small abnormal parathyroid gland is increasingly common and heralds operative complexity. World J Surg. 2014;38(6):1274–1281. doi: 10.1007/s00268-014-2450-1.
    1. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet. 1980;1(8182):1317–1320. doi: 10.1016/S0140-6736(80)91783-3.
    1. Ohe MN, Santos RO, Barros ER, Lage A, Kunii IS, Abrahão M, Cervantes O, Hauache OM, Lazaretti-Castro M, Vieira JGH. Changes in clinical and laboratory findings at the time of diagnosis of primary hyperparathyroidism in a University Hospital in Sao Paulo from 1985 to 2002. Braz J Med Biol Res. 2005;38(9):1383–1387. doi: 10.1590/S0100-879X2005000900013.
    1. Palmer M, et al. Patients with primary hyperparathyroidism operated on over a 24-year period: temporal trends of clinical and laboratory findings. J Chronic Dis. 1987;40(2):121–130. doi: 10.1016/0021-9681(87)90063-4.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe